Akeso (AKESF) said its experimental lung cancer treatment ivonescimab improved overall survival compared with a widely used ...

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to ...

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, ...

(Corrects executive designation in paragraph 6 to "chief medical officer" from "chief scientific officer") By Mariam Sunny and Kamal Choudhury May 31 (Reuters) - An experimental drug developed by ...

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an ...

A study by the University of Barcelona has discovered why the two main types of lung cancer—adenocarcinoma of the lung and ...

Summit said Harmoni-6 is the first Phase 3 study to show a "statistically significant" survival advantage over a PD-1 ...

Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.

Squamous cell carcinoma treatment varies by stage, involving surgery, radiation, and systemic therapies based on cancer progression and patient health. Stage 1 focuses on tumor removal, Stage 2 ...